Evidence map›Paper›PMID 21387003›Full record

ArticlePloS one2011

Taking pain out of NGF: a "painless" NGF mutant, linked to hereditary sensory autonomic neuropathy type V, with full neurotrophic activity.

Simona Capsoni, Sonia Covaceuszach, Sara Marinelli, Marcello Ceci, Antonietta Bernardo, Luisa Minghetti, Gabriele Ugolini, Flaminia Pavone, Antonino Cattaneo

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers.

0numbers the graph read from it
0cells of the map it votes in
49citing papers in PubMed
3.9field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

49 citing papers in PubMed, 100 citations in OpenAlex.

  1. Toward an NGF-based therapy for Rett syndrome.Frontiers in neuroscience · 2026
    Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. A Vicious NGF-p75International journal of molecular sciences · 2023
    Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. The development of somatosensory neurons: Insights into pain and itch.Current topics in developmental biology · 2021
    Review
  16. Article
  17. Article
  18. Review
  19. The NGFThe Journal of neuroscience : the official journal of the Society for Neuroscience · 2019
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 1 country.

Simona CapsoniEuropean Brain Research Institute, Rome, Italy.
Sonia Covaceuszach
Sara Marinelli
Marcello Ceci
Antonietta Bernardo
Luisa Minghetti
Gabriele Ugolini
Flaminia Pavone
Antonino Cattaneo
European Brain Research Institute · ITIstituto Superiore di Sanità · ITConsorzio Roma Ricerche · ITNeuroscience Institute · ITScuola Normale Superiore · IT

Funding

Telethon GGP05234
6 · The paper itself

Abstract

During adulthood, the neurotrophin Nerve Growth Factor (NGF) sensitizes nociceptors, thereby increasing the response to noxious stimuli. The relationship between NGF and pain is supported by genetic evidence: mutations in the NGF TrkA receptor in patients affected by an hereditary rare disease (Hereditary Sensory and Autonomic Neuropathy type IV, HSAN IV) determine a congenital form of severe pain insensitivity, with mental retardation, while a mutation in NGFB gene, leading to the aminoacid substitution R100W in mature NGF, determines a similar loss of pain perception, without overt cognitive neurological defects (HSAN V). The R100W mutation provokes a reduced processing of proNGF to mature NGF in cultured cells and a higher percentage of neurotrophin secreted is in the proNGF form. Moreover, using Surface Plasmon Resonance we showed that the R100W mutation does not affect NGF binding to TrkA, while it abolishes NGF binding to p75NTR receptors. However, it remains to be clarified whether the major impact of the mutation is on the biological function of proNGF or of mature NGF and to what extent the effects of the R100W mutation on the HSAN V clinical phenotype are developmental, or whether they reflect an impaired effectiveness of NGF to regulate and mediate nociceptive transmission in adult sensory neurons. Here we show that the R100 mutation selectively alters some of the signaling pathways activated downstream of TrkA NGF receptors. NGFR100 mutants maintain identical neurotrophic and neuroprotective properties in a variety of cell assays, while displaying a significantly reduced pain-inducing activity in vivo (n = 8-10 mice/group). We also show that proNGF has a significantly reduced nociceptive activity, with respect to NGF. Both sets of results jointly contribute to elucidating the mechanisms underlying the clinical HSAN V manifestations, and to clarifying which receptors and intracellular signaling cascades participate in the pain sensitizing action of NGF.

Indexed as

Amino Acid SubstitutionAnimalsArginineBALB 3T3 CellsCells, CulturedChick EmbryoGenetic Predisposition to DiseaseHereditary Sensory and Autonomic NeuropathiesHumansMaleMiceMutant ProteinsNerve Growth FactorsPainPain PerceptionPC12 CellsArginineMutant ProteinsNerve Growth FactorsReceptor, Nerve Growth FactorTryptophan

Identifiers

PMID21387003
PMCPMC3046150
OpenAlexW2040414086

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.